Where is American Stem Cell's headquarters?
American Stem Cell's headquarters is located at 11014 Bar X Trail, Helotes.
What is American Stem Cell's latest funding round?
American Stem Cell's latest funding round is Grant.
How much did American Stem Cell raise?
American Stem Cell raised a total of $2.5M.
Who are the investors of American Stem Cell?
Investors of American Stem Cell include Texas Emerging Technology Fund.
Who are American Stem Cell's competitors?
Competitors of American Stem Cell include Minerva Biotechnologies, Apitope, Animal Cell Therapies, Noveome Biotherapeutics, DNAtriX, NGM Biopharmaceuticals, Endocyte, Aerie Pharmaceuticals, CureTech, Celtaxsys and 42 more.
You May Also Like
Noveome Biotherapeutics is regenerative medicine company focused on the research, development and clinical use of its technology platform, derived from human placental cells. This platform provides a new approach to tissue regeneration and repair in a wide range of medical conditions. Noveome's technology platform is derived from a population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.
Enox Biopharma is a biotechnology company that developed a drug eluting technology suitable for treatment of acute and antibiotic resistant ear infection in children.
Minerva Biotechnologies developd biochips: nanoparticles coated with functionalized affinity surfaces. Minerva has developed user-friendly nanoparticles that the end user can utilize as a "black box technology". The nanoparticle system can be fully automated and a range of nanoparticles have been developed so that the readout is compatible with existing lab equipment.
ARC Pharmaceuticals Inc. is a privately owned biotechnology company developing medical products for the treatment of proliferative diseases. The Company holds exclusive intellectual property related to the treatment of surgical adhesions, rheumatoid arthritis, osteoarthritis and psoriasis. ARC's initial focus is on the prevention of surgical adhesion disease, a major complication in a high proportion of common surgical procedures causing pain and dysfunction in millions of patients worldwide.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.